Stifel analyst James Condulis raised the firm’s price target on X4 Pharmaceuticals (XFOR) to $10 from $7.50 and keeps a Buy rating on the shares as the firm transferred coverage of the stock. The firm’s “bullish thesis” is based on a view that, after a significant transformation of the company in recent months, X4 “finally has the right team” to develop, launch and sell a hematology-focused asset and necessary capital and strategy through a potential launch in 2028, the new analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XFOR:
- X4 Pharmaceuticals price target raised to $5 from $3.50 at H.C. Wainwright
- X4 Pharmaceuticals Focuses on Chronic Neutropenia Trial
- X4 Pharmaceuticals price target lowered to $7.50 from $9 at Stifel
- X4 Pharmaceuticals reports Q3 EPS (69c), consensus (84c)
- X4 Pharmaceuticals 45.87M share Spot Secondary priced at $2.85